Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases the amount of acid produced in the stomach.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
* Treatment of heartburn and acid indigestion associated with GERD.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. Dosing for longer than 12 months may be necessary.
* **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** 40 mg orally twice daily initially. Doses may be adjusted based on clinical response. Doses up to 240 mg daily have been administered intravenously.
* **Heartburn associated with GERD:** 20 mg orally once daily for up to 14 days.
## Pediatric Dosing
Dosing in pediatric patients varies based on age and indication. Consult specific pediatric guidelines for appropriate dosing. For example:
* **GERD (12 years and older):** 40 mg orally once daily for up to 8 weeks.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 40 mg orally once daily.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Co-administration with rilpivirine.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and flatulence. Long-term PPI use may be associated with an increased risk of C. difficile infection, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Rilpivirine:** Pantoprazole increases the pH of the stomach, which may decrease the absorption and antiviral efficacy of rilpivirine. Concomitant use is contraindicated.
* **Drugs dependent on gastric pH for absorption (e.g., ketoconazole, itraconazole, iron salts, digoxin):** Pantoprazole may alter the absorption of these drugs.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Consider temporary discontinuation of pantoprazole.
* **Warfarin:** PPIs may increase the INR and prothrombin time of patients receiving warfarin. Monitor INR closely.
* **CYP2C19 Substrates (e.g., clopidogrel):** Pantoprazole is a moderate inhibitor of CYP2C19 and may reduce the efficacy of clopidogrel.
## Monitoring
* Monitor for signs and symptoms of C. difficile-associated diarrhea.
* Monitor serum magnesium levels periodically, especially with prolonged use (typically >3 months).
* Monitor bone mineral density in patients at risk for osteoporosis.
* Assess for signs and symptoms of vitamin B12 deficiency with long-term therapy.
* For patients on warfarin, monitor INR closely.
## Clinical Pearls
* Administer pantoprazole orally 30 minutes before a meal.
* Do not crush or chew delayed-release capsules; swallow whole.
* For intravenous administration, reconstitute and further dilute as per manufacturer instructions.
* The risk of fracture, C. difficile infection, and hypomagnesemia increases with higher doses and longer durations of PPI therapy.
***
*This information is intended for healthcare professionals and does not substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
